Submissions tagged with docking
(5 documents)
Prediction of Evolutionarily important catalytic amino acid of Mycobacterium tuberculosis O-Succinylbenzoate synthase through in silico mutational analysis
The emergence of tuberculosis resistant to multiple, first- and second-line antibiotics poses challenges to a global control strategy that relies on standard drug treatment regimens. The high drug-...
Received 17 September 2009 10:51 UTC; Posted 18 September 2009
Posted to: Biotechnology, Microbiology, Pharmacology, Bioinformatics
Computational binding mechanism of Mycobacterium tuberculosis UDP-NAG enolpyruvyl transferase (MurA) with inhibitors fosfomycin, cyclic disulfide analog RWJ-3981, pyrazolopyrimidine analog RWJ-110192, purine analog RWJ-140998, 5-sulfonoxy-anthranilic aci
Worldwide, tuberculosis (TB) remains the most frequent and important infectious disease causing morbidity and death. One-third of the world’s population is infected with Mycobacterium tuberculosis …
Received 08 September 2009 05:44 UTC; Posted 08 September 2009
Posted to: Biotechnology, Microbiology, Bioinformatics
Studies on Regioselective Binding Mode of Steroid Molecules in Homology Modeled Cytochrome P450-2C11
In this study, we investigated the regioselective binding mode of steroid molecules and structure requirements for steroid molecules for 16α-hydroxylation by Cytochrome P450-2C11. Docking stu…
Received 03 August 2009 05:39 UTC; Posted 03 August 2009
Posted to: Chemistry, Bioinformatics
An Olfactory Receptor Pseudogene whose Function emerged in Humans
Human olfactory receptor, hOR17-210, is identified as a pseudogene in the human genome. Experimental data has shown however, that the gene product of cloned hOR17-210 cDNA was able to bind an odora…
Received 02 November 2007 21:20 UTC; Posted 05 November 2007
Posted to: Biotechnology, Neuroscience, Bioinformatics
Molecular Static and Dynamic Analyses reveal Flaw in Murine Model used by US FDA to Detect Drug Carcinogenicity
The US FDA currently accepts carcinogenicity studies of pharmaceutical drugs based on murine models. In addition to 6 month studies with p53(+/-) and ras.H2 transgenic mice, lifetime studies (typic…
Received 15 June 2007 18:05 UTC; Posted 15 June 2007
Posted to: Biotechnology, Cancer, Immunology, Pharmacology, Bioinformatics
